Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein (a)

American Heart Journal

Volumn 130, Issue 6, 1995, Pages 1168-1173

  Yamamoto, Hideya ^a   Imazu, Michinori ^a   Yamabe, Takashi ^a   Ueda, Hironori ^a   Hattori, Yoshihiro ^a   Yamakida, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISOSORBIDE DINITRATE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TURBIDIMETRY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONSTRICTION, PATHOLOGIC; CORONARY DISEASE; FEMALE; HUMAN; LIPOPROTEIN(A); MALE; MIDDLE AGE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0028892844     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(95)90138-8     Document Type: Article

References (37)

1. Guidelines for percutaneous transluminal coronary angioplasty
2. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia
3. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
4. Lp(a) lipoprotein as a risk factor for myocardial infarction
5. Association of level of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
6. Serum Lp(a) level as predictor of vein graft stenosis after coronary artery bypass surgery in patients
7. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study patients
8. A prospective study of lipoprotein (a) and risk of myocardial infarction
9. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells
10. Lipoprotein (a), fibrin binding, and plasminogen activation
11. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty
12. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty
13. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty
14. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease
15. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology
16. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man
17. ApoE4 polymorphism increases the risk of exercise-induced silent myocardial ischemia in older men
18. Report of the joint ISFC/WHO task force on coronary angioplasty
19. Guidelines for percutaneous transluminal coronary angioplasty
20. Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype
21. Evidence for reduced fibrinolytic activity in unstable angina at rest: clinical, biochemical and angiographical correlates
22. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis
23. Proliferation of human smooth muscle cells promoted by lipoprotein (a)
24. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration
25. Multivessel coronary angioplasty: classification, results, and patterns of restenosis in 494 consecutive patients
26. Serum lipoprotein levels fail to predict postangioplasty recurrent coronary artery stenosis
27. Insulin and atheroma
28. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease
29. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-1
30. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood institute
31. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis
32. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty
33. Restenosis after transluminal coronary angioplasty: a risk factor analysis
34. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation
35. Apolipoprotein E4 homozygosity is an important determinant of restenosis after coronary angioplasty
36. Restenosis after successful percutaneous transluminal coronary angioplasty
37. Transient changes of serum lipoprotein (a) as an acute phase protein